About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Los Angeles | 16,901 Studies Near You | Clareo Health

Clinical Trials LocationsLos Angeles

Clinical Trials in Los Angeles

Discover 16,901 clinical trials near Los Angeles, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4161-4180 of 16,901 trials

COMPLETEDEARLY Phase 1< 1 mile

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Secondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis

University of California, Los Angeles23 participantsStarted Apr 2022

Los Angeles, California, United States

TERMINATEDPhase 3< 1 mile

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Neovascular Age-related Macular Degeneration

Opthea Limited986 participantsStarted Mar 2021

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +188 more locations

Find Trials by Condition in Los Angeles

Breast Cancerin Los Angeles Lung Cancerin Los Angeles Prostate Cancerin Los Angeles Colorectal Cancerin Los Angeles Melanomain Los Angeles Leukemiain Los Angeles Lymphomain Los Angeles Pancreatic Cancerin Los Angeles Ovarian Cancerin Los Angeles Brain Cancerin Los Angeles

Data from ClinicalTrials.govTerms

TERMINATEDPhase 1/2< 1 mile

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

Advanced Solid Tumors

Bristol-Myers Squibb5 participantsStarted Nov 2023

Los Angeles, California, United States • Athens, Georgia, United States • Hackensack, New Jersey, United States +6 more locations

Enrolling By InvitationPhase 3< 1 mile

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

AbbVie1,200 participantsStarted Jan 2022

Huntsville, Alabama, United States • Saraland, Alabama, United States • Little Rock, Arkansas, United States +110 more locations

RECRUITINGNA< 1 mile

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

NCT06175104

Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.

Heart Defects, CongenitalAnxiety in PregnancyDepression, Postpartum+2 more

Children's Hospital Medical Center, Cincinnati50 participantsStarted Jul 2025

Los Angeles, California, United States • Cincinnati, Ohio, United States • Randwick, New South Wales, Australia +1 more locations

COMPLETEDNA< 1 mile

Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome

NCT02122328

The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant method, selective laser photocoagulation of communicating vessels (SLPCV), may provide vascular stability to the donor fetus. The primary objective is to evaluate the perinatal outcome, specifically, donor intrauterine survival of TTTS managed by SQLPCV vs. SLPCV in a prospective, randomized trial.

Twin Twin Transfusion Syndrome

University of Southern California642 participantsStarted Jun 2010

Los Angeles, California, United States

Enrolling By InvitationPhase 2< 1 mile

Impact of a Medical-Financial Partnership Intervention on Parent Mental Health, Perinatal Outcomes, and Child Developmental Risk

NCT07064915

Poverty and financial stress are key social drivers of health and root causes of worse health beginning in pregnancy, continuing into childhood, and extending over the life course, but clinical tools to address the health impacts of poverty and financial stress are needed. This trial is of a multi-site medical-financial partnership intervention to examine its effect on parent, perinatal, and child outcomes, as well as health care utilization, and family financial and social risk. This pragmatic randomized clinical effectiveness trial will examine the impact of a clinic-based medical-financial partnership intervention beginning either 1) in the newborn period (Intervention Arm 1) or 2) during prenatal care (Intervention Arm 2) versus controls on parent, child, and family/household outcomes.

Child DevelopmentMental Health

University of California, Los Angeles1,200 participantsStarted Jul 2025

Harbor City, California, United States • Los Angeles, California, United States • Sylmar, California, United States +1 more locations

Enrolling By Invitation< 1 mile

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

NCT05962398

The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).

CSL Behring56 participantsStarted Aug 2023

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +25 more locations

RECRUITINGNA< 1 mile

TEE and Dysphagia in Lung Transplantation

NCT06089434

The primary outcome of this study is dysphagia (difficulty swallowing) on postoperative speech and swallow evaluation following lung transplantation. Transesophageal echocardiography (TEE) (creates pictures of the heart from inside the participants body) is routinely performed for all lung transplantations at the University of California, Los Angeles (UCLA) and it is the standard of care. Patients are randomized to two groups. The intervention group would limit the number of TEE clips (# pictures taken) per case. The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist. The investigators hypothesize that reduction in TEE imaging during lung transplantation will reduce dysphagia.

Lung TransplantDysphagia

University of California, Los Angeles116 participantsStarted Jul 2024

Los Angeles, California, United States

COMPLETEDNA11 miles

Improving Depression Management

NCT05050227

Depression is disabling and affects one in five Veterans. VA's Primary Care-Mental health Integration (PC-MHI) enables specialists to support medication treatment in primary care, but timely and sufficient access to psychotherapy is unattainable despite Veteran preference for psychotherapy. This study aims to close the gap in psychotherapy access for VA primary care patients with depression by adapting and pilot testing PC-MHI collaborative care models to improve uptake of computerized cognitive behavioral therapy (cCBT).

VA Office of Research and Development57 participantsStarted Nov 2021

West Los Angeles, California, United States

COMPLETEDPhase 413 miles

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

NCT03915964

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Rheumatoid Arthritis

Eli Lilly and Company2,663 participantsStarted Apr 2019

Flagstaff, Arizona, United States • Gilbert, Arizona, United States • Glendale, Arizona, United States +258 more locations

COMPLETED14 miles

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

NCT05902494

This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

Urothelial Carcinoma

Seagen, a wholly owned subsidiary of Pfizer389 participantsStarted Jun 2023

Phoenix, Arizona, United States • Orange, California, United States • Palo Alto, California, United States +20 more locations

Active Not RecruitingPhase 216 miles

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03113487

This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving p53MVA and pembrolizumab together may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.

Recurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal Carcinoma

City of Hope Medical Center29 participantsStarted Feb 2018

Duarte, California, United States

COMPLETEDPhase 116 miles

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

Breast CancerPancreas CancerProstate Cancer+6 more

Novita Pharmaceuticals, Inc.23 participantsStarted Dec 2017

Scottsdale, Arizona, United States • Duarte, California, United States • New York, New York, United States

COMPLETEDPhase 1/216 miles

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Prostatic Neoplasms, Castration-ResistantAndrogen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic Neoplasms+1 more

Arcus Biosciences, Inc.173 participantsStarted Jul 2020

Cerritos, California, United States • Encino, California, United States • Orange, California, United States +16 more locations

COMPLETEDPhase 329 miles

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

NCT02908672

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

Hoffmann-La Roche514 participantsStarted Jan 2017

Birmingham, Alabama, United States • Tempe, Arizona, United States • Springdale, Arkansas, United States +107 more locations

Active Not RecruitingNA36 miles

Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

NCT04737616

We have recently developed and optimized a vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is establishing the Optical Coherence Tomography system's capability of capturing vaginal changes that occur before and after menopause, as well as before and after treatment with fractional-CO2 laser therapy. There are two aims of this study. Aim 1: 1\. To determine the feasibility and sensitivity of the integrated optical coherence endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women. Aim 2: To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over the course of C02 vaginal laser therapy.

Genitourinary Syndrome of Menopause

University of California, Irvine90 participantsStarted Jul 2020

Irvine, California, United States

COMPLETED101 miles

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products

NCT05394324

Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Refractive ErrorGlaucomaCataracts+1 more

Johnson & Johnson Surgical Vision, Inc.1,674 participantsStarted Jun 2022

Dothan, Alabama, United States • Bakersfield, California, United States • Bloomington, Minnesota, United States +10 more locations

COMPLETEDPhase 1320 miles

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

NCT05462522

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic sclerosis (SSc) during a multiple-ascending-dose (MAD) portion of the trial. In the MAD phase, increasing doses of study drug will be tested sequentially. For each dose tested, the MAD stage will consist of a treatment period of 12 weeks followed by either a safety follow-up period of 13 weeks or continued treatment in an optional open-label safety extension (OSE) stage of 52 weeks to assess the long-term safety. All patients in the OSE stage will receive RO7303509 and no patient will receive placebo.

Systemic Sclerosis

Genentech, Inc.56 participantsStarted Jan 2023

Palo Alto, California, United States • New York, New York, United States • Dallas, Texas, United States +22 more locations

Enrolling By InvitationNA361 miles

Temporally Interfering Electric Field Stimulation in the Treatment of Epilepsy

NCT06716866

This study investigates the potential for temporally-interfering electric field stimulation (TIEFS) to treat epilepsy. In this case series within and between subjects design, the impact of TIEFS on epilepsy biomarkers was studied in patients with medial temporal lobe epilepsy. Secondary analyses examine the underlying physiological effects of TIEF on local brain activity and brain networks.

University of California, Davis100 participantsStarted Jan 2019

Sacramento, California, United States • Atlanta, Georgia, United States • Brno, Czechia

PreviousPage 209 of 846Next

Diabetes

in Los Angeles

Heart Diseasein Los Angeles